Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -25

Novo Nordisk Stock Falls Despite Outlook Hike As Wegovy Sales Miss ...

📉 Novo Nordisk shares fell roughly 6% after oral Wegovy sales missed analyst estimates at $12.1 billion in Q2 adjusted revenue.

💰 Adjusted operating profit increased 11% to 33.39 billion kroner, reflecting strong underlying business performance despite stock decline.

📈 Full-year guidance was improved with adjusted sales expected to be down 6% to flat, narrowing the previously forecasted decline of 4% to 12%.

💊 Oral Wegovy generated 3.22 billion kroner in Q2, slightly below the 3.27 billion kroner consensus estimate from StreetAccount.

🗣️ CEO Mike Doustdar noted the oral pill has topped 5 million prescriptions since its January launch and is a key growth driver.

🌍 The oral formulation has expanded beyond the US into the United Kingdom and the United Arab Emirates markets.

⚠️ Company warned of expected US sales declines due to prescription trends, competition, reduced Medicaid coverage, and lower prices from new government agreements.

🏆 Novo Nordisk is competing closely with Eli Lilly (LLY) in the rapidly expanding GLP-1 obesity and diabetes treatment market.

📉 Recent experimental heart drug trial failure contributed to negative sentiment, though core franchise remains the primary focus.

🔍 Analysts view the stock decline as a reaction to lack of upside for the oral pill versus models rather than a fundamental deterioration.

Bullish Signals
  • Novo Nordisk reported second-quarter adjusted sales of $12.1 billion, achieving 7% growth at constant exchange rates.
  • Adjusted operating profit increased by 11% to 33.39 billion kroner in the second quarter.
  • The company successfully narrowed its full-year sales guidance, revising expectations from a 4%-12% decline to a range of down 6% to flat.
  • Oral Wegovy has achieved significant adoption with over 5 million prescriptions filled since its January launch.
  • Management described the oral formulation as a key growth driver for the company's future expansion.
  • The product has successfully expanded into new international markets including the UK and UAE.
Risk Factors
  • Oral Wegovy sales of 3.22 billion kroner missed analyst expectations of 3.27 billion kroner, causing shares to fall 6%.
  • The company warned that US sales are expected to decline due to current prescription trends for GLP-1 medicines and intensifying competition.
  • Reduced Medicaid coverage for obesity treatments poses a risk to future revenue streams in the United States.
  • Recent failure of an experimental heart drug in late-stage clinical trials contributed to negative investor sentiment.
Full Analysis
Novo Nordisk shares dropped approximately 6% on Tuesday following the release of its second-quarter financial results, which showed a miss in oral Wegovy sales despite an improved full-year outlook. The Danish pharmaceutical giant reported adjusted Q2 sales of 78.49 billion Danish kroner ($12.1 billion), representing 7% growth at constant exchange rates, and adjusted operating profit rose 11% to 33.39 billion kroner. While the company narrowed its guidance for full-year adjusted sales to a decline of 6% to flat (improving from a previous forecast of 4% to 12% decline) and revised operating profit outlook to a maximum decline of 6%, investors reacted negatively to specific oral Wegovy performance. The oral formulation generated 3.22 billion kroner in Q2 sales, falling slightly below analyst expectations of 3.27 billion kroner, overshadowing the broader positive trajectory of the company's semaglutide franchise. Management highlighted that the oral pill has surpassed 5 million prescriptions since its January launch and is expanding into new markets like the UK and UAE. However, Novo Nordisk issued warnings regarding future US sales due to intensifying competition, reduced Medicaid coverage for obesity treatments, and lower realized prices resulting from a 'most favored nation' pricing agreement with the Trump administration. The earnings release occurs as investors closely monitor both Novo Nordisk and rival Eli Lilly for signs of sustained demand in the competitive GLP-1 market. Additionally, recent setbacks include the failure of an experimental heart drug in late-stage trials, though investor sentiment remains primarily tied to the performance of the company's core semaglutide products.